血管免疫母细胞性T细胞淋巴瘤中RHOA-VAV1信号通路的激活
在50-70%的血管免疫母细胞性T细胞淋巴瘤(AITL)中存在G17V RHOA突变。本研究通过高通量筛选发现VAV1是G17V RHOA特异性结合伙伴,G17V RHOA与VAV1结合通过磷酸化174Tyr增强其衔接蛋白功能,加速T细胞受体(TCR)信号传导;在85例RHOA突变阴性样本中7例(8.2%)检出VAV1突变或VAV1-STAP2易位,达沙替尼可阻断加速的VAV1磷酸化及相关TCR信号。
要点
- G17V RHOA通过结合VAV1并磷酸化174Tyr增强TCR信号。
- 85例RHOA突变阴性样本中7例(8.2%)检出VAV1突变或VAV1-STAP2易位。
- 达沙替尼可阻断G17V RHOA和VAV1-STAP2引起的VAV1磷酸化及TCR信号加速。
核心结论
- G17V RHOA-VAV1轴可能为AITL提供新的治疗靶点。
研究设计与样本
- 本研究通过高通量筛选鉴定G17V RHOA特异性结合伙伴,并在85例RHOA突变阴性样本和41例RHOA突变阳性样本中检测VAV1突变及VAV1-STAP2易位。
主要发现
- G17V RHOA与VAV1结合通过磷酸化174Tyr增强其衔接蛋白功能,加速TCR信号传导。
- G17V RHOA表达可见细胞因子和趋化因子相关通路富集。
- 85例RHOA突变阴性样本中7例(8.2%)检出VAV1突变或VAV1-STAP2易位,而41例RHOA突变阳性样本均未检出VAV1突变。
- VAV1-STAP2同样显示174Tyr磷酸化增强。
- 达沙替尼有效阻断G17V RHOA和VAV1-STAP2表达引起的VAV1磷酸化加速及相关TCR信号。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Somatic G17V RHOA mutations were found in 50-70% of angioimmunoblastic T-cell lymphoma (AITL). The mutant RHOA lacks GTP binding capacity, suggesting defects in the classical RHOA signaling. Here, we discovered the novel function of the G17V RHOA: VAV1 was identified as a G17V RHOA-specific binding partner via high-throughput screening. We found that binding of G17V RHOA to VAV1 augmented its adaptor function through phosphorylation of 174Tyr, resulting in acceleration of T-cell receptor (TCR) signaling. Enrichment of cytokine and chemokine-related pathways was also evident by the expression of G17V RHOA. We further identified VAV1 mutations and a new translocation, VAV1-STAP2, in seven of the 85 RHOA mutation-negative samples (8.2%), whereas none of the 41 RHOA mutation-positive samples exhibited VAV1 mutations. Augmentation of 174Tyr phosphorylation was also demonstrated in VAV1-STAP2. Dasatinib, a multikinase inhibitor, efficiently blocked the accelerated VAV1 phosphorylation and the associating TCR signaling by both G17V RHOA and VAV1-STAP2 expression. Phospho-VAV1 staining was demonstrated in the clinical specimens harboring G17V RHOA and VAV1 mutations at a higher frequency than those without. Our findings indicate that the G17V RHOA-VAV1 axis may provide a new therapeutic target in AITL.
引用
- Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, et al. Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia. 2017. PMID: 28832024. doi:10.1038/leu.2017.273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。